MENA Gaucher Disease Treatment Market Size, Share, Trends, & Industry Analysis Report By Type (Type 1, Type 3, and Type 2), By Therapy, By Distribution Channel, By Country – Market Forecast, 2025–2034

The MENA Gaucher disease treatment market size is expected to reach USD 178.35 million by 2034, according to a new study by Polaris Market Research. The report “MENA Gaucher Disease Treatment Market Size, Share, Trends, Industry Analysis Report By Type (Type 1, Type 3, and Type 2), By Therapy, By Distribution Channel, By Country – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Gaucher disease is a rare genetic disorder caused by a deficiency of the enzyme glucocerebrosidase, leading to the accumulation of glucocerebroside in cells, particularly in the spleen, liver, bone marrow, and sometimes the brain.

The awareness about rare diseases such as Gaucher has grown significantly across the MENA. Public health campaigns, medical conferences, and rare disease advocacy groups have helped educate both healthcare providers and the public. This has led to earlier diagnosis, especially for Type 1 Gaucher disease, which is treatable with timely intervention. Countries such as Saudi Arabia and the UAE have started incorporating genetic screening programs into public healthcare services, increasing the chances of identifying cases early. The demand for effective treatment options is rising as more cases are diagnosed at the right time, thereby driving the market growth.

Governments in the MENA are increasingly prioritizing rare diseases within national healthcare strategies. Countries such as Saudi Arabia, the UAE, and Qatar have invested in centralized healthcare systems and national registries to track and manage genetic disorders. Health policy reforms now emphasize early detection, access to orphan drugs, and partnerships with global pharmaceutical companies. These supportive policies are creating an enabling environment for both local and international companies to introduce Gaucher disease therapies. Additionally, government funding for high-cost treatments such as enzyme replacement therapy (ERT) makes them more accessible to eligible patients, thereby driving the market growth.

MENA Gaucher Disease Treatment Market Report Highlights

The type 1 segment, by type, dominated the market and reached USD 104.09 million in 2024. Type 1 Gaucher disease is the most common and treatable form, which is driving demand for early diagnosis and long-term treatment in the MENA countries.

The substrate reduction therapy segment, based on therapy, held a 25.76% share in 2024 as SRT is gaining popularity in the region as an alternative for patients who cannot tolerate enzyme replacement therapy (ERT).

The Saudi Arabia Gaucher disease treatment market accounted for a 21.62% market share in 2024 due to the country’s strong healthcare infrastructure, rising government focus on rare diseases, and growing investments in genomic medicine supporting early diagnosis and treatment.

The Turkey Gaucher disease treatment market is expected to reach USD 24.79 million by 2034 due to its large population, expanding pharmaceutical sector, and strong medical education system.

A few of the key market players are Amicus Therapeutics, Inc.; CANbridge Life Sciences Ltd.; Eli Lilly and Company; Johnson & Johnson, Inc.; Lingyi Biotechnology; Protalix Biotherapeutics Inc.; Sanofi; Spur Therapeutics; Takeda Pharmaceutical; and ISU Abxis.

Polaris Market Research has segmented the MENA Gaucher disease treatment market report on the basis of type, therapy, distribution channel, and region:

By Type (Revenue – USD Million, 2020–2034)

Type 1

Type 3

Type 2

By Therapy (Revenue – USD Million, 2020–2034)

Enzyme Replacement Therapy (ERT)

Substrate Reduction Therapy (SRT)

Others

By Distribution Channel (Revenue – USD Million, 2020–2034)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Country Outlook (Revenue – USD Million, 2020–2034)

Algeria

Iraq

Iran

Saudi Arabia

Morocco

Libya

Egypt

Turkey

Rest of MENA